Division of Infectious Diseases II and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Aliment Pharmacol Ther. 2019 Oct;50(8):872-884. doi: 10.1111/apt.15449. Epub 2019 Aug 4.
Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved.
To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver METHODS: We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years.
The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune-related adverse events involving the liver are a growing concern related to their widespread use.
Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.
免疫检查点抑制剂在过去几年中彻底改变了肿瘤学领域。其可能的应用包括治疗肝细胞癌和胆管癌。不幸的是，这些药物的使用与新的免疫相关不良反应相关，肝脏是最常受累的器官之一。
提供免疫检查点抑制剂对肝脏潜在影响的概述。
我们回顾了过去 5 年在大多数相关肝病会议上关于免疫检查点抑制剂的文献和摘要/报告。
免疫检查点抑制剂的作用已被研究用于治疗病毒性肝炎和原发性肝癌。在不久的将来，这些药物在治疗肝细胞癌和慢性乙型肝炎方面具有最大的潜力。然而，与它们的广泛使用相关的是，涉及肝脏的免疫相关不良事件日益受到关注。
免疫检查点抑制剂是一类令人兴奋的新药，目前在恶性和非恶性肝病中的应用有限。对于潜在严重免疫不良反应的出现必须谨慎。
